ADMA Biologics, Inc. (ADMA)

Sage Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	459.38	426.45	258.22	154.08	80.94	42.22
Revenue Growth (YoY)	62.22%	65.16%	67.58%	90.36%	91.72%	43.85%
Cost of Revenue	217.84	206.9	167.17	118.82	79.77	53.79
Gross Profit	241.54	219.55	91.04	35.27	1.17	-11.57
Selling, General & Admin	87.09	78.37	62.59	70.3	55.19	39.22
Research & Development	2.19	1.81	3.3	3.61	2.85	5.91
Operating Expenses	89.5	80.57	66.61	74.63	58.75	45.84
Operating Income	152.04	138.98	24.43	-39.37	-57.57	-57.41
Interest Expense	-12.14	-13.93	-25.03	-19.28	-13.06	-11.99
Interest & Investment Income	2.32	2.1	1.62	0.05	0.04	0.29
Other Non Operating Income (Expenses)	-0.22	-0.19	-0.29	-0.64	-0.25	-0.13
EBT Excluding Unusual Items	142.01	126.96	0.74	-59.23	-70.85	-69.24
Merger & Restructuring Charges	-	-	-	-	-	-7.5
Asset Writedown	-	-	-2.1	-	-	-
Other Unusual Items	-1.24	-1.24	-26.87	-6.67	-0.8	0.99
Pretax Income	140.76	125.71	-28.24	-65.9	-71.65	-75.75
Income Tax Expense	-66.01	-71.96	-	-	-	-
Net Income	206.77	197.67	-28.24	-65.9	-71.65	-75.75
Net Income to Common	206.77	197.67	-28.24	-65.9	-71.65	-75.75
Shares Outstanding (Basic)	235	233	224	198	140	86
Shares Outstanding (Diluted)	245	243	224	198	140	86
Shares Change (YoY)	8.72%	8.65%	13.19%	41.77%	62.03%	58.51%
EPS (Basic)	0.88	0.85	-0.13	-0.33	-0.51	-0.88
EPS (Diluted)	0.84	0.81	-0.13	-0.33	-0.51	-0.88
Free Cash Flow	90.64	110.45	4.03	-73.42	-125.88	-114.73
Free Cash Flow Per Share	0.37	0.45	0.02	-0.37	-0.90	-1.33
Gross Margin	52.58%	51.48%	35.26%	22.89%	1.45%	-27.41%
Operating Margin	33.10%	32.59%	9.46%	-25.55%	-71.13%	-135.99%
Profit Margin	45.01%	46.35%	-10.94%	-42.77%	-88.52%	-179.41%
Free Cash Flow Margin	19.73%	25.90%	1.56%	-47.65%	-155.52%	-271.74%
EBITDA	159.94	147.03	32.76	-32.25	-52.08	-53.47
EBITDA Margin	34.82%	34.48%	12.69%	-20.93%	-64.34%	-126.65%
D&A For EBITDA	7.9	8.05	8.33	7.11	5.5	3.94
EBIT	152.04	138.98	24.43	-39.37	-57.57	-57.41
EBIT Margin	33.10%	32.59%	9.46%	-25.55%	-71.13%	-135.99%
Revenue as Reported	-	-	-	-	-	42.22

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q